This is the development pipeline as of October 24, 2024
1. Oncology
As of October 24, 2024
| Product Name/ Development Code/ Generic Name |
Mechanism | Dosage Form | Target Indication | Phase* | Area | Licensor | |||
|---|---|---|---|---|---|---|---|---|---|
| Ⅰ | Ⅱ | Ⅲ | F | ||||||
| Opdivo Intravenous Infusion |
Anti-PD-1 antibody | Injection | Hepatocellular carcinoma |
|
JP | In-house (Co-developed with BMS) |
|||
|
|
KR | ||||||||
| Bladder cancer |
|
JP・KR・TW | |||||||
| Rhabdoid tumor |
|
JP | |||||||
| Yervoy Injection★ |
Anti-CTLA-4 antibody | Injection | Hepatocellular carcinoma |
|
JP | Co-developed with BMS | |||
|
|
KR | ||||||||
| Gastric cancer |
|
JP・KR・TW | |||||||
| Urothelial cancer |
|
JP・KR・TW | |||||||
| ONO-7913/ magrolimab |
Anti-CD47 antibody | Injection | Pancreatic cancer★ |
|
JP | Gilead | |||
| Colorectal cancer★ |
|
JP | |||||||
| ONO-4482★/ relatlimab |
Anti-LAG-3 antibody | Injection | Melanoma |
|
JP | Co-developed with BMS | |||
| Hepatocellular carcinoma |
|
JP・KR・TW | |||||||
| ONO-7475/ tamnorzatinib |
Axl/Mer inhibitor | Tablet | Pancreatic cancer★ |
|
JP | In-house | |||
| EGFR-mutated non-small cell lung cancer |
|
JP | |||||||
| ONO-4578 | PG receptor (EP4) antagonist | Tablet | Gastric cancer★ |
|
JP・KR・TW | In-house | |||
| Colorectal cancer★ |
|
JP | |||||||
| Pancreatic cancer★ |
|
JP | |||||||
| Non-small cell lung cancer★ |
|
JP | |||||||
| Hormone receptor-positive, HER2-negative breast cancer |
|
JP | |||||||
| ONO-7427★ | Anti-CCR8 antibody | Injection | Solid tumor |
|
JP | Co-developed with BMS | |||
| ONO-7914★ | STING agonist | Injection | Solid tumor |
|
JP | In-house | |||
| ONO-4059 | Bruton‘s tyrosine kinase (BTK) inhibitor | Tablet | Primary central nervous system lymphoma |
|
US | In-house | |||
| ONO-4685 | PD-1×CD3 bispecific antibody | Injection | T-cell lymphoma |
|
JP・US | In-house | |||
| ONO-7018 | MALT1 inhibitor | Tablet | Non-Hodgkin lymphoma, Chronic lymphocytic leukemia |
|
JP・US | Chordia | |||
| ONO-4538HSC | Anti-PD-1 antibody | Injection | Solid tumor |
|
JP | Co-developed with BMS | |||
| ONO-8250 | iPSC-derived HER2 CAR T-cell therapy | Injection | HER2-expressing Solid tumor |
|
US | Fate | |||
★Combination with Opdivo.
※In the case of clinical development of the oncology drugs in the same indication, the most advanced clinical phase is described.
- Ⅰ:Phase 1、Ⅱ:Phase 2、Ⅲ:Phase 3:、F:Filed
2. Areas other than Oncology
As of October 24, 2024
| Product Name/ Development Code/ Generic Name |
Mechanism | Dosage Form | Target Indication | Phase* | Area | Licensor | |||
|---|---|---|---|---|---|---|---|---|---|
| Ⅰ | Ⅱ | Ⅲ | F | ||||||
| Velexbru Tablets/ Tirabrutinib Hydrochloride |
Bruton‘s tyrosine kinase (BTK) inhibitor | Tablet | Pemphigus |
|
JP | In-house | |||
| ONO-2017/ cenobamate |
Inhibition of voltage-gated sodium currents/positive allosteric modulator of GABAA ion channel | Tablet | Primary generalized tonic-clonic seizures |
|
JP | SKBP | |||
| Partial-onset seizures |
|
JP | |||||||
| ONO-2910 | Enhancement of Schwann cell differentiation | Tablet | Chemotherapy-Induced Peripheral Neuropathy |
|
JP | In-house | |||
| ONO-2808 | S1P5 receptor agonist | Tablet | Multiple System Atrophy |
|
JP・US | In-house | |||
| ONO-4685 | PD-1×CD3 bispecific antibody | Injection | Autoimmune disease |
|
JP・EU | In-house | |||
| ONO-2020 | Epigenetic Regulation | Tablet | Neurodegenerative disease |
|
US | In-house | |||
| ONO-1110 | Endocannabinoid regulation | Oral | Pain |
|
JP | In-house | |||
| ONO-4915 | PD-1×CD19 bispecific antibody | Injection | Autoimmune disease |
|
JP | In-house | |||
- Ⅰ:Phase 1、Ⅱ:Phase 2、Ⅲ:Phase 3:、F:Filed
3. Deciphera(Subsidiary)
Learn more about Deciphera pipeline →
As of October 24, 2024
| Product Name/ Development Code/ Generic Name |
Mechanism | Dosage Form | Target Indication | Phase* | Area | Licensor | |||
|---|---|---|---|---|---|---|---|---|---|
| Ⅰ | Ⅱ | Ⅲ | F | ||||||
| Qinlock／ripretinib | KIT inhibitor | Tablet | GIST 2nd KIT Exon 11+17/18 |
|
NA・SA・EU・AU・KR・TW | Deciphera | |||
| DCC-3014／vimseltinib | CSF-1R inhibitor | Tablet | TGCT |
**
|
NA・EU・AU・HK | Deciphera | |||
| DCC-3116 | ULK inhibitor | Tablet | Solid tumor（with sotorasib） |
|
US | Deciphera | |||
| Solid tumor（with ripretinib） |
|
US | |||||||
| DCC-3084 | Pan-RAF inhibitor | Tablet | Solid tumor |
|
US | Deciphera | |||
- Ⅰ:Phase 1、Ⅱ:Phase 2、Ⅲ:Phase 3:、F:Filed
- NA : North America, SA : South America, AU : Australia, SG : Singapore, HK : Hong Kong, KR : Korea, TW : Taiwan, JP : Japan
- FDA, EMA Filing accepted